Cargando…
Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder
BACKGROUND AND OBJECTIVES: Neuromyelitis optica spectrum disorder (NMOSD) is a disabling autoimmune neurologic disease. Anti–IL-6 receptor (IL-6R) therapy prevents relapses in patients with anti–aquaporin 4 (AQP4)-IgG-positive NMOSD; however, it remains unclear how cellular immune components are alt...
Autores principales: | Matsuoka, Takako, Araki, Manabu, Lin, Youwei, Okamoto, Tomoko, Gold, Ralf, Chihara, Norio, Sato, Wakiro, Kimura, Atsuko, Tachimori, Hisateru, Miyamoto, Katsuichi, Kusunoki, Susumu, Yamamura, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691226/ https://www.ncbi.nlm.nih.gov/pubmed/37863660 http://dx.doi.org/10.1212/NXI.0000000000200173 |
Ejemplares similares
-
Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study
por: Araki, Manabu, et al.
Publicado: (2014) -
Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica
por: Chihara, Norio, et al.
Publicado: (2013) -
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder
por: Yamashita, Kazuya, et al.
Publicado: (2018) -
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
por: Araki, Manabu, et al.
Publicado: (2012) -
Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders
por: Miyamoto, Katsuichi, et al.
Publicado: (2023)